In a devastating blow to investor confidence, Moderna’s shares experienced a dramatic decline of up to 22 per cent on Monday following disappointing sales forecasts from the US biotech giant.
In a devastating blow to investor confidence, Moderna’s shares experienced a dramatic decline of up to 22 per cent on Monday following disappointing sales forecasts from the US biotech giant.






